Opinion|Videos|November 17, 2026

Twice-Yearly HIV Therapy: Lenacapavir Plus Broadly Neutralizing Antibodies

A twice-yearly regimen could transform HIV treatment, but durability, susceptibility testing, clinic capacity, and reimbursement must all be resolved before it becomes part of routine care.

"Twice-Yearly HIV Therapy: Lenacapavir Plus Broadly Neutralizing Antibodies" takes up the question of what must be true before every-six-month HIV treatment becomes standard practice.

Dr. Burkhart notes that lenacapavir combined with long-acting broadly neutralizing antibodies, or bNAbs, has entered phase 3 trials. His first clinical requirement is durability. Every component must last the full six months. If one wanes early, the patient could effectively be left on monotherapy. He also explains that bNAbs target specific viral strains. Patients may need genotypic or phenotypic testing to confirm susceptibility, which adds cost and must be resolved.

Operationally, clinics must prepare for more patients coming in for administration. That may require additional staffing and routine reminder calls so patients do not miss injections. Reimbursement also has to be settled in advance. Clinicians need to know whether the therapy will be billed through prescription coverage, the medical benefit, or buy-and-bill.

Dr. Burkhart then describes ideal and less suitable candidates. Patients with pill fatigue are strong candidates, since one visit every six months is easier than daily pills. Patients concerned about stigma may prefer not to keep pill bottles at home. Less suitable candidates include those with viral resistance to the components. Patients with histories of missed appointments or unstable housing are also concerning, because missed visits could force treatment restarts.

Dr. Madison adds that many of those barriers can be addressed. Clinicians can offer bus passes, peer buddies, or community health workers to help patients navigate challenges and keep appointments. She stresses that individualized care remains central. She reflects that she once hoped for a cure in her lifetime. Given these newer agents, she is now hopeful for a functional cure. Dr. Nguyen adds that research on an mRNA HIV vaccine is underway. If approved, it would be the first HIV vaccine.

In "Two-Drug HIV Regimens, Archived M184V Resistance, and Long-Acting Preference," the panel will weigh archived resistance before two-drug simplification and what patients reveal when offered injectables.

Funding supported by Gilead. Content independently developed by Pharmacy Times.


Related to this article